BARCELONA, SpainReal-world data on a new pulsed-field catheter ablation system for the treatment of atrial fibrillation (AF) suggest that roughly four out of every five patients will be free from AF, atrial flutter (AFL), or atrial tachycardia (AT) at 1 year.
Clinical outcomes were better in those with paroxysmal rather than persistent AF, but use of the Farapulse pulsed-field ablation system (Boston Scientific) was safe in the overall cohort, with investigators observing no esophageal damage or pulmonary vein (PV) stenosis in this large, unselected patient population.
Vivek Reddy, MD (Icahn School of Medicine at Mount Sinai, New York, NY), who presented the results of the MANIFEST-PF registry during a late-breaking clinical trial session at the European Heart Rhythm Association (EHRA) 2023 meeting last week, said there are several limitations to the new retrospective study. The frequency and/or intensity of Holter monitoring in follow-up varied across the European centers. Additionally, in terms of safety, we dont know what happens when more than 10,000 patients are treated, said Reddy, noting there was one case of phrenic nerve palsy that lasted beyond hospitalization and out to 1 year.
Carlos Morillo, MD (University of Calgary/Libin Cardiovascular Institute, Canada), the scheduled discussant following Reddys presentation, agreed that broader safety data are still needed. The single case of phrenic nerve palsy is a little bit of a red flag, he said, adding that while pulsed-field ablation might be the promised land, we may see some other complications in the future.
Clinical trials testing various pulsed-field ablation systems for the treatment of AF are beginning to emerge. At the recent American College of Cardiology/World Congress of Cardiology 2023 meeting, researchers showed that use of the PulseSelect ablation system (Medtronic) safely and effectively reduced the recurrence of atrial arrhythmias in those with persistent and paroxysmal AF.
Pulsed-field ablation is a nonthermal ablation technique where short bursts of high-power electrical fields are applied to the targeted tissue. This destabilizes the cell membranes by creating irreversible nanoscale pores that ultimately result in cell death, while the use of nonthermal energy helps prevent damage to surrounding structures. Catheter ablation of AF is a safe procedure in the hands of experienced operators, but complications can arise, including PV stenosis, phrenic nerve palsy, and atrioesophageal fistula, with the use of thermal energy sources such as radiofrequency energy, cryotherapy, or lasers.
Right now, there are no approved pulsed-field ablation systems in the United States, but several are currently under development or are available in Europe, including Farapulse and PulseSelect.
Best Results in Paroxysmal AF
In 2022, investigators published survey results from 24 European centers participating in the MANIFEST-PF registry. Of 1,758 patients treated with pulsed-field ablation, the acute success rate was 99.9%, with zero reports of esophageal complications, PV stenosis, or phrenic nerve paralysis. However, it was a center-level analysis and no long-term efficacy data was reported, said Reddy.
The new analysis is a retrospective patient-level study of 1,568 individuals (mean age 64.5 years; 35% female) from the MANIFEST-PF registry who had persistent and paroxysmal AF treated with pulsed-field ablation after CE Mark approval of the Farapulse ablation catheter. As opposed to the prior analysis, it includes only patients undergoing a first ablation for AF. Overall, mean left ventricular EF was preserved in these patients, with a median left atrial diameter of 42 mm, and approximately 40% were taking class I/III antiarrhythmic drug therapy before ablation.
Acute success was very high at 99.2%, said Reddy. All patients underwent PV isolation, with 11% of patients also undergoing ablation in the left atrial posterior wall. A very small percentage of patients received additional ablative lines, including the roof and mitral lines, as well as ablation of the cavotricuspid isthmus. The energy used to perform these non-PV ablations was largely pulsed-field energy (85%). Procedure time was roughly 1 hour, with a total fluoroscopy time of 12 minutes.
After a median follow-up of 367 days, freedom from AF/AFL/AT was 78.1% in the entire cohort. When stratified by AF subtype, freedom from AF/AFL/AT was 81.6% in those with paroxysmal AF and 71.5% in those with persistent AF. Among patients with nonparoxysmal AF, 12-month outcomes were 71.3% for those with persistent AF and 73.5% for those with long-standing, persistent AF. Reddy cautioned, though, that relatively few patients (3%) in MANIFEST-PF had long-standing, persistent AF.
In the full cohort, 70.8% of patients were free from AF/AFL/AT, antiarrhythmic drug therapy, or redo ablation at 12 months. In the persistent and paroxysmal subgroups, those numbers were 65.1% and 73.8%, respectively. The rate of major adverse events was 1.9%, with tamponade observed in 1.1% of cases. Strokes were very rare (0.4%).
Importance of Durable PV Isolation
Reddy noted that while they did not observe any relationship between hospital volume and freedom from AF/AFL/AT, they did see better outcomes in centers that appeared to achieve more durable PV isolation. Hospitals were classified as having either a high ( 50%) or low (< 50%) rate of durable PV isolation based on an analysis of patients undergoing redo procedures. Centers that had a high rate of durable PV isolation had a significantly higher success rate in terms of freedom from AF/AFL/AT than centers with a low rate (81% vs 71%; P = 0.001).
There was about a 10-point difference, said Reddy. This was true in the full cohort, and also true if you separate by paroxysmal and persistent [atrial fibrillation].
During the discussion, Morillo said these data emphasize the importance of PV isolation for preventing future AF. Overall, he said, the results from the registry are outstanding, particularly those seen in patients with persistent AF. Even in long-standing persistent atrial fibrillation, which was only 3% [of the entire cohort], the results are quite reassuring, said Morillo. Having said that, the monitoring strategy was relatively limited with a median of two or three [follow-ups with 24-hour Holter monitoring].
Finally, Morillo said he would like to see more data on how women fared with the procedure, noting that women with persistent AF have historically not responded as well to catheter ablation.
See the original post:
Pulsed-Field Ablation Cuts AF Recurrence at 1 Year: MANIFEST-PF ... - TCTMD
- Best 30 Cardiology in Secaucus, NJ with Reviews - YP.com - April 12th, 2018 [April 12th, 2018]
- Cardiology | Weill Cornell Medicine - April 14th, 2018 [April 14th, 2018]
- Cardiology Conferences 2018 | Cardiology Meetings 2018 ... - April 26th, 2018 [April 26th, 2018]
- Dr. Anil Goel, MD - Birmingham, MI - Cardiology & Clinical ... - April 26th, 2018 [April 26th, 2018]
- Clinical Physiology (Cardiology) MSc/PGDip | Middlesex ... - May 15th, 2018 [May 15th, 2018]
- Cardiology Conferences 2018 | Upcoming Cardiology ... - May 16th, 2018 [May 16th, 2018]
- Clinical Cardiology Section | Cleveland Clinic - May 27th, 2018 [May 27th, 2018]
- Journal of Clinical and Experimental Cardiology - Open ... - June 6th, 2018 [June 6th, 2018]
- Cardiology Summit 2018 | Cardiology Conferences | Heart ... - June 23rd, 2018 [June 23rd, 2018]
- Cardiology Clinical and Research Faculty Members ... - June 26th, 2018 [June 26th, 2018]
- Cardiology Conferences 2018 | Cardiology Congress 2018 ... - June 26th, 2018 [June 26th, 2018]
- About Us - New Jersey Cardiology Associates - July 8th, 2018 [July 8th, 2018]
- About Us - Ventura Clinical Trials - August 16th, 2018 [August 16th, 2018]
- Clinical Cardiology Made Ridiculously Simple: Michael A ... - August 22nd, 2018 [August 22nd, 2018]
- Clinical Cardiology - American Society of Preventive Cardiology - October 2nd, 2018 [October 2nd, 2018]
- Heart Surgery Hospital in india | Cardiology Treatment ... - October 7th, 2018 [October 7th, 2018]
- Clinical Cardiology - American Society of Preventive ... - December 3rd, 2018 [December 3rd, 2018]
- Guideline Clinical App - American College of Cardiology - December 7th, 2018 [December 7th, 2018]
- Journal of Clinical and Experimental Cardiology- Open ... - December 12th, 2018 [December 12th, 2018]
- Clinical Cardiology - Baptist Health - December 30th, 2018 [December 30th, 2018]
- Cardiology at Cancun: Topics in Clinical Cardiology - February 5th, 2019 [February 5th, 2019]
- Department of Cardiovascular Medicine, KU School of Medicine - March 10th, 2019 [March 10th, 2019]
- Towards Health Equality: Improving the Management of Cardiovascular Diseases in Women - International Atomic Energy Agency - September 21st, 2019 [September 21st, 2019]
- Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors - TCTMD - September 21st, 2019 [September 21st, 2019]
- DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF - TCTMD - September 21st, 2019 [September 21st, 2019]
- Combining Nature and Technology, Luye Medical and Cleveland Clinic Join to Build a Future Hospital in Shanghai - Yahoo Finance - September 21st, 2019 [September 21st, 2019]
- Will Renal Denervation for Hypertension Rise Again? - Medscape - September 21st, 2019 [September 21st, 2019]
- Obstructive Sleep Apnea, Sleep Symptoms, and their Association with Cardiovascular Disease - DocWire News - September 21st, 2019 [September 21st, 2019]
- CNE expands pulmonary, sleep services with Brigham & Women's physicians - Warwick Beacon - September 21st, 2019 [September 21st, 2019]
- What I Am Most Looking Forward to at TCT 2019 - TCTMD - September 21st, 2019 [September 21st, 2019]
- Serelaxin Not Linked to CV Mortality Reduction in Patients Hospitalized for Acute HF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Sacubitril-Valsartan Not Linked to Lower Hospitalization Risk, CV Death in HFpEF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- FDA clears multiuse angiography systems from Siemens Healthineers - DOTmed HealthCare Business News - September 21st, 2019 [September 21st, 2019]
- Balloon Pulmonary Angioplasty Effective for Chronic Thromboembolic PH - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- RWJBarnabas Health, St. Luke's University Health launch clinical affiliation - FierceHealthcare - September 21st, 2019 [September 21st, 2019]
- Bilirubin: A Novel Indicator of Infective Endocarditis Adverse Outcomes - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS - TCTMD - September 21st, 2019 [September 21st, 2019]
- Community-based Care Model Reduces CVD Risk - Managed Healthcare Executive - September 21st, 2019 [September 21st, 2019]
- American College of Cardiology Steps Up: Equal Pay, Opportunities for All - TCTMD - September 21st, 2019 [September 21st, 2019]
- FDA Approves Novo Nordisk's Oral Semaglutide, First GLP-1 in Pill Form - AJMC.com Managed Markets Network - September 21st, 2019 [September 21st, 2019]
- A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Cred - Medscape - September 21st, 2019 [September 21st, 2019]
- Seeking Synergy: Bringing Cardiology into Your Enterprise Imaging Strategy - Health Imaging - September 21st, 2019 [September 21st, 2019]
- TCT 2019 Day Two: Transcatheter Valves, New and Old - TCTMD - September 30th, 2019 [September 30th, 2019]
- Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis - TCTMD - September 30th, 2019 [September 30th, 2019]
- Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival - Diagnostic and Interventional Cardiology - September 30th, 2019 [September 30th, 2019]
- TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3 - TCTMD - September 30th, 2019 [September 30th, 2019]
- Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy... - September 30th, 2019 [September 30th, 2019]
- Off Script: The New Gatekeepers of Procedural Education - TCTMD - September 30th, 2019 [September 30th, 2019]
- Study Shows Safety and Efficacy of Near Infrared Spectroscopy (NIRS) Imaging to Identify Patients and Plaques at an Increased Risk for MACE - BioSpace - September 30th, 2019 [September 30th, 2019]
- The Heart of the Matter: Cardiovascular Fitness in Horses - United States Eventing Association - September 30th, 2019 [September 30th, 2019]
- Google parent Alphabet hires former FDA head Robert Califf to lead health strategy and policy - FierceHealthcare - September 30th, 2019 [September 30th, 2019]
- Inclisiran Benefits Patients With Familial Hypercholesterolemia and ASCVD - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- AUGUSTUS: Best Benefit With Apixaban, P2Y12 Inhibitor Dual Therapy - Medscape - September 30th, 2019 [September 30th, 2019]
- New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis - Newswise - September 30th, 2019 [September 30th, 2019]
- Dapagliflozin Improves Heart Failure-Related Health Status in HFrEF - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Remote Ischemic Conditioning Did Not Improve 12 Month Clinical Outcomes After STEMI - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Insights from the European Society of Cardiology congress | Speaking of Medicine - PLoS Blogs - September 30th, 2019 [September 30th, 2019]
- Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- AZ's Farxiga gets heart failure prevention okay from FDA - PMLiVE - October 22nd, 2019 [October 22nd, 2019]
- Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019 - BioSpace - October 22nd, 2019 [October 22nd, 2019]
- The Epidemic Of The Metabolic Syndrome Among The Palestinians In The G | DMSO - Dove Medical Press - October 22nd, 2019 [October 22nd, 2019]
- Optina Diagnostics and the Montreal Heart Institute Partner to Develop a New Biomarker for Atherosclerosis - PRNewswire - October 22nd, 2019 [October 22nd, 2019]
- Even With Same Diagnosis, Women Get Half the Heart Attack Treatments as Men - AJMC.com Managed Markets Network - October 22nd, 2019 [October 22nd, 2019]
- Eva Dickerman, Andrew Weil - The New York Times - October 22nd, 2019 [October 22nd, 2019]
- EHR vendor Veradigm and partners creating new shared data tools for researchers - Healthcare IT News - October 22nd, 2019 [October 22nd, 2019]
- Evolocumab Well-tolerated as Add-on for Hypercholesterolemia Therapy - DocWire News - October 22nd, 2019 [October 22nd, 2019]
- Deborah Heart and Lung Center announces affiliation with Cleveland Clinic Heart & Vascular Institute - Health Essentials from Cleveland Clinic - October 22nd, 2019 [October 22nd, 2019]
- New Registry to Provide Insight into STEMI Occurrence, Treatment in North India | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- Finding Your Best Fit in Cardiology - TCTMD - October 22nd, 2019 [October 22nd, 2019]
- Cardiology team expands to meet community need - The Union of Grass Valley - October 22nd, 2019 [October 22nd, 2019]
- Deaths After Ablation of Atrial Fibrillation 'Concerning' in Real-World Analysis - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cutler Family gifts $15 million to University Hospitals to transform mens health care - Newswise - November 1st, 2019 [November 1st, 2019]
- Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD - TCTMD - November 1st, 2019 [November 1st, 2019]
- Caregiving and the Soul of Medicine - Medscape - November 1st, 2019 [November 1st, 2019]
- STEMI Mortality Unaffected by Weekend, Weeknight, or Holiday Admission in France - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical publishes positive results from the AMBULATE pivotal study Cardiology2.0 - Cardiology2.0 - November 1st, 2019 [November 1st, 2019]
- Gaps in Access to TAVR and SAVR: 'Something Needs to Be Done' - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical Announces Publication of Data From the AMBULATE Pivotal Study in the Journal of the American College of Cardiology: Clinical... - November 1st, 2019 [November 1st, 2019]
- Raymond James 4 Analyst Favorite Health Care Picks With Huge Upside Potential - 24/7 Wall St. - November 7th, 2019 [November 7th, 2019]
- Global Computed Tomography (CT) Scanners Devices and Equipment Market Report 2020: Major Players are GE Healthcare, Koninklijke Philips, Hitachi,... - November 7th, 2019 [November 7th, 2019]